Dr. DeCastro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
20 Duke Medicine Circle
Durham, NC 27710Phone+1 919-684-8964- Is this information wrong?
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1988 - 1991
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1985 - 1988
- University of Texas Southwestern Medical SchoolClass of 1985
- Duke UniversityB.S., Engineering, Summa Cum Laude, 1977 - 1981
Certifications & Licensure
- NC State Medical License 1991 - 2024
- TX State Medical License 1986 - 2004
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Best Doctors in America 2009
- NIH Physicians Scientist Award 1991
- Dean’s List Duke University, 1977-1980
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsDose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.Kathryn Elizabeth Hudson, David A. Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis F. Diehl, Joseph O. Moore, Carlos M. DeCastro, Anne W. Beaven> ;British Journal of Haematology. 2019 Feb 1
- 10 citationsPhase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed ...Sascha A. Tuchman, Joseph O. Moore, Carlos D. DeCastro, Zhiguo Li, Emily Sellars, Yubin Kang, Gwynn D. Long, Cristina G. Gasparetto> ;Journal of Geriatric Oncology. 2017 May 1
- 5 citationsPhase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed d...Danielle M. Brander, David A. Rizzieri, Jon P. Gockerman, Louis F. Diehl, Thomas C. Shea, Carlos M. DeCastro, Joseph O. Moore, Anne W. Beaven> ;Leukemia & Lymphoma. 2013 Mar 14
- Join now to see all
Journal Articles
- A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapyGriffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE, American Journal of Hematology, 1/1/2015
- A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myelomaHeld LA. Rizzieri D. Long GD. Gockerman JP. Diehl LF. de Castro CM. Moore JO. Horwitz ME. Chao NJ. Gasparetto C, Cancer Investigation, 1/1/2013
- Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuriaHillmen P, Muus P, Roth A, Elebute MO, Risitanon AM, Schrezenmeter H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socie G, Brodsky RA, Brit J Haematol, 1/1/2013
- Join now to see all
Abstracts/Posters
- The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.Christensen DJ, Bond KM, Volkheimer AD, Oddo J, Chen Y, Gockerman JP, Moore JO, Diehl LF, de Castro CM, Vitek MP, Weinberg JB, Blood, 1/1/2009
- Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.Lancet JE, Komrokji RS, Lin HY, de Castro CM, Rizzieri DA , Melchert M, List AF, Blood, 1/1/2009
- A phase II pilot stury of sorafenib in patients with myelodysplastic syndromes.de Castro C, Adams D, Rizzieri D, Moore J, Gockerman J, Diehl L, Horwitz M, Edmonds E, Warzecho J, Leukemia Research, 1/1/2009
- Join now to see all
Lectures
- Paroxysmal Nocturnal Hemoglobinuria- Lessons from a Rare DiseaseMoffitt Cancer Center, Tampa, FL - 1/21/2009
- Visiting Professorship Lectures for Hematology/Oncology Fellows: MDSUniversity of Florida College of Medicine, Gainsville, FL - 1/19/2009
- Epigenetic Therapy for Myelodysplastic SyndromesShanghai, China - 1/18/2009
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Duke University HospitalDurham, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: